<DOC>
	<DOCNO>NCT00154245</DOCNO>
	<brief_summary>The study one-year prospective , open-label , safety efficacy study . De novo renal transplant recipient receive cyclosporine , 1.44g EC-MPS ( 720 mg b.i.d . ) , corticosteroids .The study consist 12-month open-label treatment period EC-MPS .</brief_summary>
	<brief_title>A One-year , Open Label Study Investigate Safety Effect Enteric-coated Mycophenolate Sodium ( EC-MPS ) Combination With Cyclosporine Microemulsion de Novo Kidney Transplant Recipients .</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Males female age 1875 year . Recipients de novo cadaveric , live unrelated living relate kidney transplant Multiorgan recipient ( e.g . kidney pancreas ) previous transplant organ . Patients recipient ABO incompatible transplant . Patients historical current peak PRA 50 % . Patients already exist antibody HLAtype receive transplant . Evidence severe liver disease ( incl . abnormal liver profile i.e . AST , ALT total bilirubin 3 time UNL ) . Patients HIV Hepatitis B surface antigen positive . Patients know hypersensitivity mycophenolic acid , MMF , ECMPS , component formulation ( e.g . lactose ) . Patients thrombocytopenia ( 75,000/mm3 ) , absolute neutrophil count &lt; 1,500/mm3 , and/or leukocytopenia ( &lt; 2,500/mm3 ) , and/or hemoglobin &lt; 6 g/dL Screening Baseline . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Enteric-coated mycophenolate sodium , transplantation , de novo , cyclosporine</keyword>
</DOC>